March 4th, 2020 | 07:27 CET
Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
In the fight against cancer
The name Medigene is certainly known to many traders. The German biotech company is engaged in therapies for the treatment of various types of cancer in different stages. The T-cell-focused immune therapies are the focus of Medigene. Starting in the field of blood cancers, the company is pursuing a strategy of initiating its own clinical development programmes.
In addition, therapeutic approaches are being sought with selected partners to enable successful treatment of tumors. The market value of Medigene is currently around EUR 110 million. The Medigene share is an investment in cancer research.
Increasing the chances of having children
More and more couples worldwide are desperately longing in vain for a child of their own. Modern medicine has developed various possibilities and procedures to successfully initiate pregnancy. The so-called in vitro fertilisation, also known as IVF procedure, is one possibility of artificial insemination. In this procedure, the ovum is taken from the woman and then artificially fertilized with the man's sperm in the laboratory. If the fertilization is successful, the embryos can then be transferred to the uterus so that pregnancy can begin.
In order to increase the chances of a successful pregnancy, the separation of high-quality sperm is purposeful. The Australian company Memphasys has developed a product that can be used to process the seminal fluid to increase the birth rate. The product called FELIX is currently being tested by experts and sales are expected to start in the second half of 2020. Memphasys currently has a market value of around EUR 25 million. The Memphasys shares enable investors to support couples' desire to have children and benefit from the success of the product.
Expert in molecular information
In connection with the current corona virus, the biotech company Qiagen can offer test solutions that can diagnose whether a patient is infected within an hour. The company is represented in 25 countries around the globe and employs 4,700 people.
According to Medigene, the company offers 500 products that enable physicians, scientists and laboratory staff to examine and research the molecules of the human body for various purposes. The company has more than 500,000 customers in its more than 30-year history. The market value of Qiagen is currently EUR 7.3 billion. Qiagen's stock is the focus of the hype surrounding the current corona virus and a takeover bid by Thermo Fisher. Investors can see price gains.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.